Investigation of Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-6856 in Healthy Participants, Including a Subset of Healthy Japanese Participants
Latest Information Update: 16 Apr 2025
At a glance
- Drugs NNC0113-6856 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 10 Apr 2025 Planned End Date changed from 6 Jun 2025 to 17 Jun 2025.
- 10 Apr 2025 Planned primary completion date changed from 6 Jun 2025 to 17 Jun 2025.
- 26 Oct 2023 Status changed from not yet recruiting to recruiting.